Omecamtiv mecarbil in chronic heart failure with reduced ejection fraction: GALACTIC-HF baseline characteristics and comparison with contemporary clinical trials

Simple item page
dc.contributor.authorTeerlink, John R.
dc.contributor.authorDiaz, Rafael
dc.contributor.authorFelker, G. Michael
dc.contributor.authorMcMurray, John J. V.
dc.contributor.authorMetra, Marco
dc.contributor.authorSolomon, Scott D.
dc.contributor.authorAdams, Kirkwood F.
dc.contributor.authorAnand, Inder
dc.contributor.authorArias-Mendoza, Alexandra
dc.contributor.authorBiering-Sorensen, Tor
dc.contributor.authorBohm, Michael
dc.contributor.authorBonderman, Diana
dc.contributor.authorCleland, John G. F.
dc.contributor.authorCorbalan, Ramon
dc.contributor.authorCrespo-Leiro, Maria G.
dc.contributor.authorDahlstrom, Ulf
dc.contributor.authorEcheverria Correa, Luis E.
dc.contributor.authorFang, James C.
dc.contributor.authorFilippatos, Gerasimos
dc.contributor.authorFonseca, Candida
dc.contributor.authorGoncalvesova, Eva
dc.contributor.authorGoudev, Assen R.
dc.contributor.authorHowlett, Jonathan G.
dc.contributor.authorLanfear, David E.
dc.contributor.authorLund, Mayanna
dc.contributor.authorMacdonald, Peter
dc.contributor.authorMareev, Vyacheslav
dc.contributor.authorMomomura, Shin-ichi
dc.contributor.authorO'Meara, Eileen
dc.contributor.authorParkhomenko, Alexander
dc.contributor.authorPonikowski, Piotr
dc.contributor.authorRamires, Felix J. A.
dc.contributor.authorSerpytis, Pranas
dc.contributor.authorSliwa, Karen
dc.contributor.authorSpinar, Jindrich
dc.contributor.authorSuter, Thomas M.
dc.contributor.authorTomcsanyi, Janos
dc.contributor.authorVandekerckhove, Hans
dc.contributor.authorVinereanu, Dragos
dc.contributor.authorVoors, Adriaan A.
dc.contributor.authorYilmaz, Mehmet B.
dc.contributor.authorZannad, Faiez
dc.contributor.authorSharpsten, Lucie
dc.contributor.authorLegg, Jason C.
dc.contributor.authorAbbasi, Siddique A.
dc.contributor.authorVarin, Claire
dc.contributor.authorMalik, Fady I.
dc.contributor.authorKurtz, Christopher E.
dc.date.accessioned2025-01-23T19:47:44Z
dc.date.available2025-01-23T19:47:44Z
dc.date.issued2020
dc.description.abstractAims The safety and efficacy of the novel selective cardiac myosin activator, omecamtiv mecarbil, in patients with heart failure with reduced ejection fraction (HFrEF) is being tested in the Global Approach to Lowering Adverse Cardiac outcomes Through Improving Contractility in Heart Failure (GALACTIC-HF) trial. Here we describe the baseline characteristics of participants in GALACTIC-HF and how these compare with other contemporary trials.
dc.description.abstractMethods and results Adults with established HFrEF, New York Heart Association (NYHA) functional class >= II, ejection fraction <= 35%, elevated natriuretic peptides and either current hospitalization for heart failure or history of hospitalization/emergency department visit for heart failure within a year were randomized to either placebo or omecamtiv mecarbil (pharmacokinetic-guided dosing: 25, 37.5, or 50 mg bid). A total of 8256 patients [male (79%), non-white (22%), mean age 65 years] were enrolled with a mean ejection fraction 27%, ischaemic aetiology in 54%, NYHA class II 53% and III/IV 47%, and median N-terminal pro-B-type natriuretic peptide 1971 pg/mL. Heart failure therapies at baseline were among the most effectively employed in contemporary heart failure trials. GALACTIC-HF randomized patients representative of recent heart failure registries and trials with substantial numbers of patients also having characteristics understudied in previous trials including more from North America (n = 1386), enrolled as inpatients (n = 2084), systolic blood pressure <100 mmHg (n = 1127), estimated glomerular filtration rate <30 mL/min/1.73 m(2) (n = 528), and treated with sacubitril/valsartan at baseline (n = 1594).
dc.description.abstractConclusions GALACTIC-HF enrolled a well-treated, high-risk population from both inpatient and outpatient settings, which will provide a definitive evaluation of the efficacy and safety of this novel therapy, as well as informing its potential future implementation.
dc.fuente.origenWOS
dc.identifier.doi10.1002/ejhf.2015
dc.identifier.eissn1879-0844
dc.identifier.issn1388-9842
dc.identifier.urihttps://doi.org/10.1002/ejhf.2015
dc.identifier.urihttps://repositorio.uc.cl/handle/11534/100405
dc.identifier.wosidWOS:000583618200001
dc.issue.numero11
dc.language.isoen
dc.pagina.final2171
dc.pagina.inicio2160
dc.revistaEuropean journal of heart failure
dc.rightsacceso restringido
dc.subjectHeart failure
dc.subjectOmecamtiv mecarbil
dc.subjectCardiac myosin activator
dc.subjectInotrope
dc.subjectMyotrope
dc.subjectCardiovascular outcomes trial
dc.subject.ods03 Good Health and Well-being
dc.subject.odspa03 Salud y bienestar
dc.titleOmecamtiv mecarbil in chronic heart failure with reduced ejection fraction: GALACTIC-HF baseline characteristics and comparison with contemporary clinical trials
dc.typeartículo
dc.volumen22
sipa.indexWOS
sipa.trazabilidadWOS;2025-01-12
Files
Collections
Artículos de revistas